Newfeed

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study.With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability.Following dialogue with US regulatory authorities, Kodiak plans to conduct one

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: